
|Articles|November 1, 2003
Vitrase results presented at retinal society meeting
Irvine, CA -- Two phase III clinical trials of ovine hyaluronidase (Vitrase, ISTA Pharmaceuticals) reveal a statistically significant reduction in vitreous hemorrhage density in patients with diabetes during each of 3 months following a single intravitreous injection of ovine hyaluronidase when compared with a single injection of saline solution.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Dr. Mali’s top 5 predictions in ophthalmology for 2026
2
FDA clears Novaliq’s Investigational New Drug application for NOV05
3
Eye exams could enable earlier detection of systemic disease
4
Low-dose pilocarpine shrinks pupil without altering accommodation in presbyopia
5



























